Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 3Esophageal Squamous Cell Carcinoma 1Carcinoma 1Advanced Biliary Tract Cancer 1

Interventions

Gemcitabine 11pembrolizumab 10Oxaliplatin 7Nivolumab 7Irinotecan 7Fluorouracil 7Capecitabine 7durvalumab 6Sorafenib 6Leucovorin 6Cyclophosphamide 6Paclitaxel 5Ipilimumab 5tislelizumab 3poly ICLC 3lenvatinib 3fludarabine 3Sunitinib 3Radiotherapy 3Cisplatin 3Cetuximab 3130-nm albumin-bound paclitaxel 3seocalcitol 2selinexor 2pemigatinib 2futuximab 2fludarabine phosphate 2donafenib 2cemiplimab 2atezolizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma × sitravatinib × Gastrointestinal × Clear all
NCT03941873 2024-10-26

A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer

BeiGene

Phase 1/2 Completed
111 enrolled 22 charts
Gastrointestinal

Carcinoma, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡